Program
NM-101
A development code.
Its studies are mostly in Parkinson Disease, led by Neuramedy.
Furthest: phase 1, since Mar 6, 20232 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neuramedy | 21 open or running | phase 1since Mar 6, 2023 | Mar 6, 2023 | none ahead |
Also a collaborator on its studies: quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2023First study: phase 1 study in Parkinson DiseaseFirst studyNCT05790382 · 56 enrolled · United Kingdom
- Apr 3, 2025Phase 1 study in Healthy SubjectsNCT06934941 · 36 planned · Korea, Republic of
TargetBeta
TLR2 →read by rule
“NM-101 is an anti-TLR2 antibody which may have clinical efficacy in Parkinson's disease patients.”study text, by rule · the study
Other programs on TLR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| INNA-051rule | ena-respiratory-pty-ltd | phase 2 | 3 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06934941Healthy Subjects · Korea, Republic of | 1 | Recruiting | Oct 30, 2025 | 36 |
| NCT05790382Parkinson Disease · United Kingdom | 1 | UNKNOWN | May 30, 2024 | 56 |
How it is read
Names in the registry
- “NM-101”, 2 entries
Codes read as this program: NM101.
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.